文献速递血液净化与透析水电解质与酸碱

EOS789 广谱磷酸盐转运抑制剂在血液透析患者中的 1b 期随机交叉试验:安全且提示有效

EOS789, a broad-spectrum inhibitor of phosphate transport, is safe with an indication of efficacy in a phase 1b randomized crossover trial in hemodialysis patients.
PubMed 文献 · Kidney Int · 2020-10-31

本研究为 1b 期随机交叉试验,在血液透析患者中评估 EOS789(NaPi-2b、PiT-1、PiT-2 泛抑制剂)的安全性及对肠道磷酸盐吸收的影响。两项设计相同的交叉研究各纳入 10 例患者,分别比较 EOS789 50 mg 与安慰剂、EOS789 100 mg 与 EOS789 100 mg 联合司维拉姆 1600 mg。结果显示无研究药物相关严重不良事件,各比较组间肠道磷酸盐吸收分数无显著差异,但完成两项研究的 6 例患者中 EOS789 100 mg 组的吸收分数较安慰剂呈下降趋势。

要点

  • EOS789 在血液透析患者中安全且耐受良好,无药物相关严重不良事件。
  • EOS789 50 mg 或 100 mg 与对照相比,肠道磷酸盐吸收分数无显著差异。
  • 完成两项研究的 6 例患者中,EOS789 100 mg 组吸收分数较安慰剂呈下降趋势。

核心结论

  • EOS789 在血液透析患者中安全且耐受良好,并提示可能降低肠道磷酸盐吸收。

研究设计与样本

  • 1b 期随机交叉试验,两项设计相同的研究各纳入 10 例接受间歇性血液透析的患者。
  • 患者每日摄入含 900 mg 磷酸盐的控制饮食两周,第 4 天开始用药,第 10 天进行磷酸盐吸收测试。

主要发现

  • 未发生研究药物相关严重不良事件。
  • 肠道磷酸盐吸收分数:安慰剂 0.53(95%CI 0.39,0.67)vs EOS789 50 mg 0.49(95%CI 0.35,0.63),差异无统计学意义。
  • 肠道磷酸盐吸收分数:EOS789 100 mg 0.40(95%CI 0.29,0.50)vs EOS789 100 mg 联合司维拉姆 1600 mg 0.36(95%CI 0.26,0.47),差异无统计学意义。
  • 完成两项研究的 6 例患者中,EOS789 100 mg 组的肠道磷酸盐吸收分数较安慰剂呈下降趋势。

临床怎么用

  • EOS789 可作为血液透析患者高磷血症的潜在治疗选择,但现阶段仍需 2 期和 3 期研究验证其有效性。

局限性

  • 本研究为 1b 期小样本试验,每项研究仅 10 例患者,疗效需在更大规模研究中确认。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The treatment of hyperphosphatemia remains challenging in patients receiving hemodialysis. This phase 1b study assessed safety and efficacy of EOS789, a novel pan-inhibitor of phosphate transport (NaPi-2b, PiT-1, PiT-2) on intestinal phosphate absorption in patients receiving intermittent hemodialysis therapy. Two cross-over, randomized order studies of identical design (ten patients each) compared daily EOS789 50 mg to placebo with meals and daily EOS789 100 mg vs EOS789 100 mg plus 1600 mg sevelamer with meals. Patients ate a controlled diet of 900 mg phosphate daily for two weeks and began EOS789 on day four. On day ten, a phosphate absorption testing protocol was performed during the intradialytic period. Intestinal fractional phosphate absorption was determined by kinetic modeling of serum data following oral and intravenous doses of 33Phosphate (33P). The results demonstrated no study drug related serious adverse events. Fractional phosphate absorption was 0.53 (95% confidence interval: 0.39,0.67) for placebo vs. 0.49 (0.35,0.63) for 50 mg EOS789; and 0.40 (0.29,0.50) for 100 mg EOS789 vs. 0.36 (0.26,0.47) for 100 mg EOS789 plus 1600 mg sevelamer (all not significantly different). The fractional phosphate absorption trended lower in six patients who completed both studies with EOS789 100 mg compared with placebo. Thus, in this phase 1b study, EOS789 was safe and well tolerated. Importantly, the use of 33P as a sensitive and direct measure of intestinal phosphate absorption allows specific testing of drug efficacy. The effectiveness of EOS789 needs to be evaluated in future phase 2 and phase 3 studies.

来源:Kidney Int,查看原文。版权归原作者所有。

引用

  1. Hill Gallant KM, Stremke ER, Trevino LL, et al. EOS789, a broad-spectrum inhibitor of phosphate transport, is safe with an indication of efficacy in a phase 1b randomized crossover trial in hemodialysis patients. Kidney Int. 2020. PMID: 33137340. doi:10.1016/j.kint.2020.09.035

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。